Abstract 75P
Background
The sodium-dependent phosphate transporter NaPi2b is a promising target for the treatment of malignant tumors due to its increased expression in several oncological diseases. NaPi2b is a target for therapeutic monoclonal antibodies directed against the MX35 epitope within the large extracellular domain (ECD) of the NaPi2b. We assume that this epitope has tumor-specific conformation that is formed due to the creation of disulfide bonds between four cysteine residues at positions 303, 322, 328 and 350. The proline residue at position 325 lies between cysteines 322 and 328 in the region of the MX35 epitope of NaPi2b. We assume that proline at this position due to its formation of a bend in the structure of the peptide participates in the formation of a disulfide bond between cysteines at positions 322 and 328 that is critical in the recognition of the MX35 epitope by antibodies. To verify this, the mutant form with the proline replacement should be evaluated using antibodies against the MX35 epitope in Western blot and microscopy analysis. The aim of this work was to create a genetic construct encoding the mutant form of the NaPi2b transporter with the replacement of proline with alanine at position 325.
Methods
To carry out site-directed mutagenesis, we selected primers with the replacement of triplets encoding proline at position 325 with a triplet encoding alanine in the SLC34A2 (encoding transporter NaPi2b) gene. The resulting PCR product was transformed into E.coli cells of the XL1-Blue strain and plasmid DNA was isolated. To confirm the mutation, samples were sequenced using the Sanger method.
Results
As a result of our work, we created a genetic construct with the replacement of proline with alanine at position 325 of the NaPi2b transporter, which will be further test in Western blot and microscopy analysis by monoclonal antibodies.
Conclusions
The obtained results supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030) are important for further study of the mechanism of recognition of the MX35 NaPi2b epitope by monoclonal antibodies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract